Skip to content

Acute effects of MDMA on trust, cooperative behaviour and empathy: A double-blind, placebo-controlled experiment.

Anna Borissova, Bart Ferguson, Matthew B. Wall, Celia Ja Morgan, Robin Carhart-Harris, Mark Bolstridge, Michael AP Bloomfield, Tim M Williams, Amanda Feilding, Kevin Murphy, Robin J. Tyacke, David Erritzøe, Lorna Stewart, Kim Wolff, David Nutt, Helen Valerie Curran, Will Lawn

Journal of Psychopharmacology June 15, 2020 DOI: 10.1177/0269881120926673 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Double-blind, repeated-measures, placebo-controlled experiment Peer reviewed
Sample size 20
Population Healthy volunteers
Intervention MDMA
Dose 100 mg MDMA-HCl
Duration Two acute sessions one week apart, each followed by a subacute session three days later
Topics MDMA
Keywords MDMA Effects MDMA Research MDMA Study MDMA Findings MDMA Impact MDMA Psychology MDMA Science MDMA Investigation Prosocial behavior Social engagement Cooperative behavior Trust Empathy Social connection Interpersonal relations Positive social interaction Prosociality Cooperative behaviour Psychedelic research Psychedelic science Psychopharmacology Drug studies Psychoactive research Psychedelic studies Psychotropic research
Citations 37
Key findings MDMA did not significantly change task-based empathy, trust, or cooperative behavior compared to placebo, despite increasing subjective feelings of closeness and euphoria and plasma MDMA levels.

Abstract

Background: 3,4-Methylenedioxymethamphetamine (MDMA) is being actively researched as an adjunct to psychotherapy. It may be beneficial to trust, empathy and cooperative behaviour due to its acute prosocial effects.

Aim: To test (a) the acute effects of MDMA on measures of empathy, trust and cooperative behaviour, and (b) subacute changes in mood three days after MDMA administration.

Methods: =7 female), participated in this double-blind, repeated-measures, placebo-controlled experiment. Participants attended two acute sessions, one week apart. Each acute session was followed by a subacute session three days later. Participants received placebo (100 mg ascorbic acid) during one acute session, and MDMA (100 mg MDMA-HCl) at the other, with order counterbalanced. Participants completed the following tasks assessing prosocial behaviour: a trust investment task, a trustworthy face rating task, an empathic stories task, a public project game, a dictator game and an ultimatum game. Participants reported subjective effects. Blood was taken pre-drug, 2 and 4 hours post-drug, and tested for plasma MDMA levels.

Results: MDMA acutely increased self-reported 'closeness to others' and 'euphoria' and increased plasma concentrations of MDMA. MDMA did not significantly change task-based empathy, trust or cooperative behaviour. Using Bayesian analyses, we found evidence that MDMA and placebo did not differ in their effects on empathy and cooperative behaviour. MDMA did not significantly change subacute mood and this was supported by our Bayesian analyses.

Conclusion: Despite augmentation in plasma MDMA levels and subjective drug effects, we found no increase in prosocial behaviour in a laboratory setting.

Comparable studies

Other randomized controlled trials on MDMA, most cited first.

Study Year Design Participants
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Patients with severe PTSD, including those with comorbidities such as dissociation,... 2021 Randomized controlled trial n = 90
The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. Patients with chronic post-traumatic stress disorder refractory to both psychotherapy... 2010 Randomized controlled trial n = 20
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Military veterans and first responders aged 18 or older with chronic PTSD lasting 6... 2018 Randomized, double-blind, dose-response, phase 2 clinical trial n = 26
A randomized, controlled pilot study of MDMA (±3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD) Patients with treatment-resistant PTSD 2012 Randomized controlled trial n = 12
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Adults with moderate to severe post-traumatic stress disorder 2023 Randomized controlled trial n = 104

Citations in the library

Explore topics